Appropriate Starting Dose of Dasatinib Based on Analyses of Dose-Limiting Toxicities and Molecular Responses in Asian Patients With Chronic Myeloid Leukemia

CONCLUSION: The starting dosage of dasatinib may need to be reduced (eg, 80 mg once daily or lower) for Asian patients with CP-CML, especially with lighter BW, to alleviate the risk of DLT occurrence without compromising the achievement of MR.PMID:33632667 | DOI:10.1016/j.clml.2021.01.020

Source: Clinical Lymphoma and Myeloma - February 26, 2021 Category: Cancer & Oncology Authors: Hyejin Shin Jung-Eun Ha Dae Young Zang Sung-Hyun Kim Young Rok Do Won Sik Lee Dong-Wook Kim Jangik I Lee Source Type: research